Objective: To estimate the effect of adjuvant chemotherapy (AC) on the prognosis in cervical cancer patients with intermediate-or high-risk factors after radical hysterectomy (RH) compared to that for adjuvant radiotherapy (AR). Methods: The Embase and MEDLINE databases and the Cochrane Library were searched for published studies comparing cervical cancer patients who received AC with those who received AR after RH. The endpoints were patient oncologic outcome. Random-effects meta-analytical models were used to calculate the pooled estimates of the effect of AC on mortality/recurrence. Results: Two randomized trials and eleven observational studies (AC, 942 patients; AR, 1,721 patients) met our search criteria. There were no significant differences in mortality and any recurrence between two groups. The results for distant recurrence favored the AC group (pooled odds ratio: 0.69; 95% confidence interval: 0.54-0.88; p=0.03). In subgroup analyses (for study design, histology, indication for adjuvant treatment, AR type, AC type, and lymph node metastasis), there was no significant increase in mortality and recurrence for AC compared with that for AR. Conclusion: Compared to AR, AC showed similar survival outcomes in cervical cancer patients undergoing RH and also appeared to reduce the risk of distant recurrence.
INTRODUCTION
The International Agency of Research on Cancer estimated that cervical cancer was the fourth most common cancer in women and the seventh overall worldwide in 2012, with an estimated 528,000 new cases. There were 266,000 cervical cancer-related deaths estimated worldwide in 2012, accounting for 7.5% of all female cancer-related deaths [1] . In Korea, there were an tumor size, deep stromal invasion (DSI), lymphovascular space invasion (LSVI), AC details (regimen, dose, cycle); AR details (dose, use of CCRT, concomitant chemotherapy regimen), follow-up duration; recurrence; death from disease; and indications for adjuvant treatment. Pathological risk factors including LNM, PMI, and RMI were considered high-risk factors [4] ; those including bulky tumor (>4 cm diameter), DSI, and LSVI were considered intermediate risk factors [5] . Each study was systematically reviewed for features that could introduce bias, similarity of risk factors for prognosis, and similarity of follow-up durations between the AC and AR groups. Three authors (KBL, SHS, and JML) independently extracted data and discrepancies were jointly reviewed until consensus was reached.
Quality assessment
For non-randomized studies (NRSs), the quality of each study was evaluated using the nine-star Newcastle-Ottawa scale (NOS) in three categories: selection, comparability, and exposure (case-control studies) or outcomes (cohort studies) [9] . Based on quality assessment standards from previous meta-analyses [10] , the present meta-analysis defined a study with five or more stars as high-quality. To evaluate the study quality for RCTs, the following features were assessed: randomization procedure, estimation of sample size, blinding and allocation concealment, loss to follow-up, dropout, and intention-to-treat analysis [11] . Study quality was quantified using the Jadad/Oxford quality scoring system [12] . Three authors (KBL, SHS, and JML) independently evaluated study quality and discrepancies were jointly reviewed until consensus was reached.
Data generation and analysis
The primary endpoint was the mortality rate. The secondary endpoints were the total, local, and distant recurrence rates. The ORs and 95% CIs for the mortality or recurrence rates for the AC and AR groups were calculated from the original data of each study. Cross-study heterogeneity was examined using the Cochran Q test and the I 2 statistic [13, 14] . Q test p<0.1 [13] or I 2 statistic >50% [14] indicated substantial heterogeneity between studies. A random-effects model was used (DerSimonian-Laird method) to estimate the combined OR [15] . Subgroup analyses according to study design (RCT or NRS), histology (squamous cell carcinoma [SCC] or adenocarcinoma [ADC] or SCC plus ADC), type of AR (RT only or CCRT only or RT plus CCRT), indications for adjuvant treatment (intermediate-risk only or highrisk only), status of LNM (yes or no), and AC regimen (platinum combination with taxane or platinum combination with non-taxane) were performed. Sensitivity analysis was conducted by withdrawing one study at a time from the meta-analysis to evaluate its effect on the pooled OR [8] . Publication bias was determined using the BeggMazumdar rank correlation [16, 17] and fail-safe N [18] tests. All analyses were performed using R version 3.0.2 (R Foundation, Vienna, Austria; http://cran.r-project.org/mirrors. html). A two-sided p value <0.05 was considered significant.
RESULTS

Literature search
From 2,057 records, 49 papers were identified for detailed full-text review. Finally, 13 studies were included in the meta-analysis [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Fig. 1 CCRT 907 of 1,652 (55%) AC, adjuvant chemotherapy; ADC, adenocarcinoma; ADSCC, adenosquamous carcinoma; AR, adjuvant radiotherapy; CCRT, concurrent chemoradiotherapy; CDDP, cisplatin; FP, fluorouracil and cisplatin; NRS, non-randomized study; NTP, nontaxane and platinum; RCT, randomized controlled trial; RT, radiation therapy; SCC, squamous cell carcinoma; TP, taxane and platinum. 
Study characteristics
Meta-analysis of the impact of AC on survival compared to that of AR
Twelve studies compared AC to AR in terms of survival, with a combined total of 486 deaths (164/920 patients receiving AC vs. 322/1,608 patients receiving AR) [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . No significant difference in mortality rates was observed between the AC and AR groups (OR=0.73; 95% CI=0.51-1.04; p=0.08), with low cross-study heterogeneity (p=0.10 and I 2 =34) ( Fig. 2A) . In the sensitivity analysis, no significant increase was found in mortality in the AC group compared to that in the AR group after any single study was omitted (Supplementary Table 4 ). There was no evidence of publication bias (p=0.55, Begg-Mazumdar rank correlation test). The fail-safe N test indicated that 18 more studies with significant findings would be needed to render the two-sided p value non-significant. The funnel plot for publication bias was asymmetric (Fig. 3A) . However, other quantified tests for publication bias indicated that t the observed overall effect is robust (p=0.55, Begg-Mazumdar rank correlation test); The fail-safe N test 184 indicated that 18 more studies with significant findings would be needed to render the 2-sided p-value non-significant. Table 2 shows the results of subgroup analyses comparing mortality rates for AC and AR. The Forest plots are shown in Supplementary Fig. 1. Supplementary Fig. 1A illustrates the ORs for AC and mortality for each study and the pooled ORs for study design (NRS or RCT Comparison of adjuvant treatment after surgery 
AC and mortality risk in subgroup meta-analyses
Meta-analysis of the impact of AC on recurrence compared with that for AR
Thirteen studies comprised a total of 2,663 patients with a combined total of 754 recurrences (253/942 patients receiving AC vs. 501/1,721 patients receiving AR) [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . No significant difference in recurrence rates was observed between the AC and AR groups (OR=0.86; 95% CI=0.67-1.11; p=0.26), with low cross-study heterogeneity (p=0.08 and I 2 =20) (Fig. 2B) . In the sensitivity analysis, no study significantly influenced the pooled OR for AC and recurrence (Supplementary Table 5 ). No publication bias was found (p=0.68, Begg-Mazumdar rank correlation test) and the funnel plot was symmetrical (Fig. 3B) .
Twelve studies assessing 2,530 patients had reported on local and distant recurrence [19-23,25-31]. No significant difference in the local recurrence rates was observed between the two groups (OR=1.20; 95% CI=0.74-1.94; p=0.46), with significant cross-study heterogeneity (p=0.02 and I 2 =50) (Fig. 2C) . No publication bias was found (p=0.84) and the funnel plot was symmetrical (Fig. 3C) . The results for distant recurrence favored the AC group (OR=0.69; 95% CI=0.54-0.88; p=0.03), with low cross-study heterogeneity (p=0.76 and I 2 =0) (Fig. 2D) . No publication bias was found (p=0.55) and the funnel plot was symmetrical (Fig. 3D) . The fail-safe N test indicated that 14 more studies with significant findings would be needed to render the two-sided p value non-significant. Table 3 shows the results of subgroup analyses comparing recurrence in AC versus that for AR. The Forest plots are illustrated in Supplementary Fig. 2. Supplementary Fig. 2A shows the ORs for AC, the recurrence for each study, and the pooled ORs for study design (NRS or RCT CCRT [20] . Pooled data from these studies revealed no significant difference between the AC and AR groups (OR=1.04; 95% CI=0.81-1.35; p=0.74), with low cross-study heterogeneity (p=0.37 and I 2 =0). Supplementary Fig. 2E shows the pooled ORs for recurrence according to the AC regimen. In 2 studies featuring platinum combination with taxane only [22, 25] Comparison of adjuvant treatment after surgery 
DISCUSSION
To the best of our knowledge, this is the first meta-analysis to comprehensively evaluate the effects of AC on oncologic outcome in cervical cancer patients with intermediate-or highrisk factors after surgery compared to those for AR. The results of our meta-analysis indicate that patients receiving AC after surgery have comparable survival outcomes and recurrence rates to those who undergo AR or adjuvant CCRT. This pattern was consistently observed in the subgroup analyses of study design, histology, AR type, indications for adjuvant treatment, LNM status, and AC regimen.
It is controversial as to whether histologic type influences survival and the pattern of recurrence in patients with early-stage cervical cancer [32] [33] [34] [35] . Although studies are limited, ADC may be more resistant when RT is added after surgery, and role of adjuvant RT for ADC remains uncertain [36] . The results of subgroup analysis including ADC plus SCC histologic type showed no significant difference in recurrence and mortality rates between groups.
Although few data specifically address the result of AC after radical surgery in patients meeting the Sedlis criteria, the literature addressing this issue reported a 3-year diseasefree survival rate of 94.6% and a 5-year cervical cancer-specific survival of 96.2% [37] . Due to discretion and experience of the gynecologic oncologists, the risk factors that indicate adjuvant treatment can differ between clinicians. In each of the analyzed studies, each group was compared with the same indications. The pooled data from these studies revealed no significant difference in mortality and recurrence rates between the AC and AR groups.
The results of retrospective studies suggested that adjuvant systemic chemotherapy treatment decreased distant recurrence when compared to CCRT for patients with highrisk factors [19, 20] . However, other studies reported that recurrence patterns and rates did not differ significantly between groups with high-risk factors [21, 23, 29, 31] . In a study of patients with intermediate risk factors, distant control was not significantly improved but local failure did not occur in the chemotherapy group [27] . In our analysis, no significant difference in local recurrence rates was observed between groups. However, distant recurrence favored the AC group (OR=0.69; 95% CI=0.54-0.88; p=0.03), with low crossstudy heterogeneity (p=0.76 and I 2 =0). If lymph node metastasis is a surrogate of distant metastasis, this result may be evidence of a direct effect of systemic chemotherapy on distant micrometastatic lesions.
Platinum is the most common active agent in the treatment of cervical cancer and platinumcontaining combination regimens, topotecan and paclitaxel combination regimens, platinum single agent, and paclitaxel single agent have been considered appropriate treatments for advanced or recurrent cervical cancer [38] . Although the optimal chemotherapeutic agents have not been determined, AC with platinum-based combination regimen were used in the included studies. The GOG 240 trial demonstrated the effects of the addition of bevacizumab to paclitaxel and cisplatin [39] . Similarly, in the Japanese Gynecologic Oncology Group (JGOG) 1,065 trial, neoadjuvant chemotherapy with nedaplatin and irinotecan were reported to have favorable response rates [40] . These data show the potential of the addition of such combination regimens in the adjuvant setting. There were no significant differences in mortality among 2 studies including platinum and taxane combination therapy (OR=0.28; 95% CI=0.03-2.44; p=0.25). In addition, the mortality in the AC group did not increase significantly in five studies that using platinum and non-taxane combinations (OR=0.67; 95% CI=0.45-0.99; p=0.04). The recurrence rates between groups did not differ significantly, irrespective of the combination regimen.
RCTs overcome numerous weaknesses associated with NRSs and provide the best available data regarding the effect of AC in surgically treated cervical cancer patients. Our metaanalysis included 2 RCTs with 3 stars in the Jadad scoring system. However, the study by Curtin et al. [31] was closed prematurely owing to insufficient accrual; the initial accrual goal was 160 patients but it enrolled only 89 patients. Thus, the data were unable to show that the AC and AR were equivalent. Similarly, the planned accrual goal after statistical sample size calculation was 160 patients for the study by Lahousen et al. [29] . Their final enrolled number was only 52, yielding suboptimal power. Recently, the JGOG launched a confirmatory clinical trial of AC in high-risk, stage IB-IIB cervical cancer after primary radical hysterectomy (JGOG 1082). If the non-inferiority of AC is confirmed in terms of survival compared with AR in this prospective trial, AC could be accepted as the new standard treatment.
Our study had several limitations; thus, the results should be interpreted with caution. First, the majority of the included studies were NRS, although 2 RCTs were also included. While we rigorously performed subgroup-analyses to control for potential confounders, unknown confounders such as surgical quality may not have been excluded. Second, the studies were conducted in different institutions with presumably varying surgical expertise. Third, it was not possible to perform a subgroup analysis of the number of AC cycles or dose of AC because of a lack of data. Therefore, the effect of AC according to these features could not be analyzed. Finally, our meta-analysis did not provide adverse events profiles related to AC or AR. No RCT directly compared adverse events between groups, but several studies suggested lower complication rates with AC [17, 20, 24] .
The results of the present meta-analysis suggest that AC showed similar survival outcomes in surgically treated cervical cancer patients and reduced the risk of distant recurrence when compared with AR. The JGOG trial may provide more evidence on the role of AC in these patients, establishing this strategy be used as an alternative standard treatment option. Comparison of adjuvant treatment after surgery Supplementary Table 2 Jadad score for the risk of bias and quality assessment of RCTs
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Supplementary Table 3 Newcastle-Ottawa scale for the risk of bias and quality assessment of non-randomized studies
Supplementary Table 4 Sensitivity analysis comparing adjuvant chemotherapy (AC) versus adjuvant radiotherapy (AR) for mortality in which one study at a time was omitted and the pooled odds ratio for all remaining studies was calculated
Supplementary Table 5 Sensitivity analysis comparing AC versus AR for recurrence in which one study at a time was omitted and the pooled OR for all remaining studies was calculated Click here to view Supplementary Fig. 1 The association between AC and mortality in subgroup meta-analyses is shown according to (A) study design, (B) histology type, (C) indication for adjuvant treatment, (D) AR type, (E) AC type, and (E) status of LNM. The size of each square is proportional to the sample size in each study, and the horizontal line through the square indicates the 95% CI for that study. For the pooled analysis, the diamond indicates the pooled value, and the right and left ends of the diamond indicate the 95% CI for the analysis.
Supplementary Fig. 2 The association between AC and recurrence in subgroup meta-analyses is shown according to (A) study design, (B) histology type, (C) indication for adjuvant treatment, (D) AR type, (E) AC type, and (E) status of LNM. The size of each square is proportional to the sample size in each study, and the horizontal line through the square indicates the 95% CI for that study. For the pooled analysis, the diamond indicates the pooled value, and the right and left ends of the diamond indicate the 95% CI for the analysis. 
